Prescient Therapeutics Ltd has appointed Melanie Farris as an independent non-executive director, further strengthening its board.
Farris is a seasoned governance and risk professional from the life sciences sector and will also serve as chair of the company’s audit and risk committee. She brings more than 18 years of experience in corporate governance, risk oversight and financial management, primarily across the biotechnology and pharmaceuticals industries.
“We are pleased to welcome Melanie to the Board of Directors, especially at this exciting time for the company. Melanie brings considerable experience in strategy, funding, governance and risk operations and oversight. Her depth of knowledge and expertise in these areas will be invaluable to the Board, shareholders and key stakeholders of Prescient. We look forward to Melanie’s contribution as Prescient continues to deliver on its mission to improve outcomes for cancer patients,” Prescient Chair, Dr James Campbell said.
Advancing its portfolio
It is a pivotal time in PTX’s development as the company advances its portfolio of personalised cancer therapies through clinical trials.
“The PTX-100 Phase 1b results demonstrated strong potential to advance to market a treatment for patients with limited options. This is an exciting time for Prescient, and I look forward to contributing with my Board colleagues and the management team in building value for the Company’s stakeholders as the Phase 2 trial progresses,” Farris said.
Her appointment follows a succession of senior roles at prominent life sciences companies, most recently at Telix Pharmaceuticals, where she held multiple executive titles.
At Telix, a global radiopharmaceutical company, Farris served as senior vice president for global governance, risk and compliance, and later as chief governance and risk officer and group company secretary. She led the organisation’s governance strategy and oversaw its internal audit, compliance and sustainability functions. Her remit included shaping Telix’s global operational risk frameworks, with a focus on aligning regulatory and ethical obligations across jurisdictions.
Prior to her time at Telix, Farris held board and executive positions with several listed and not-for-profit entities. She was a non-executive director and company secretary at Factor Therapeutics, and also served as chief financial officer, non-executive director and company secretary at Invion Limited, an ASX-listed clinical-stage drug development company.
Her experience extends to the not-for-profit sector, having chaired the board of Synapse Australia, a national organisation supporting individuals impacted by brain injury.
Farris began her professional career in the United Kingdom, where she worked in senior management and development roles outside the healthcare sector. She served as chief operating officer of FourFour Promotions, a music and events management company, and as a development executive for The Prince’s Foundation, a charitable organisation focused on community building and sustainable development.
Her diverse professional background is underpinned by formal qualifications in corporate communications and governance. She holds a Bachelor of Communication in Public Relations and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of both the Governance Institute of Australia and the Chartered Governance Institute in the United Kingdom. She is also a graduate of the Australian Institute of Company Directors.
Enhancing board capability
Prescient described Farris’ appointment as part of a broader strategy to enhance board capability and oversight as the company navigates the regulatory, clinical and commercial pathways of drug development. With clinical-stage programs underway and a focus on precision oncology, the company noted the increasing importance of disciplined risk management and transparent corporate governance.
Prescient’s chairman and managing director were not quoted in the announcement. However, the company stated that Farris’ leadership of the audit and risk committee is expected to play a central role in board-level supervision of internal controls, risk frameworks and compliance with evolving governance standards.
Farris' blend of operational experience in both large and small organisations is seen as a key asset as Prescient seeks to balance innovation with regulatory and investor expectations. Her capacity to navigate complex compliance environments and build scalable governance models was a hallmark of her tenure at Telix, where she supported the company's growth from early-stage development to commercial operations across multiple regions.
Her previous directorships at Factor Therapeutics and Invion add further weight to her understanding of the biotechnology landscape, particularly the unique challenges faced by emerging companies in maintaining financial discipline while progressing through capital-intensive R&D programs.
Farris’ appointment also reflects an industry-wide push to diversify board composition with leaders who bring both sector-specific insight and strong cross-functional capabilities. Her experience in audit and risk, sustainability reporting and organisational governance is aligned with investor expectations for increased transparency and accountability across life sciences firms.
Prescient’s board refresh comes amid growing scrutiny of clinical-stage companies’ governance frameworks, as regulatory agencies and investors demand greater oversight in how organisations manage trial risks, data integrity and ESG performance. In this context, the inclusion of a governance specialist like Farris is expected to strengthen both strategic oversight and stakeholder confidence.
The company has not indicated any additional board changes at this time. With this appointment, Farris becomes one of a select number of directors on the Prescient board with executive experience spanning both commercial and non-profit sectors.
Her multidisciplinary background and boardroom credentials mark a further evolution in Prescient’s leadership as it continues advancing novel therapies through development pipelines. The company’s current programs include targeted cell therapies and modular CAR-T platforms designed to address unmet needs in haematological and solid tumours.
Farris is expected to start her role immediately.